FDA Considers Blocking Imports from German API & Drug Facility
The Food and Drug Administration is considering refusing admission of imports of active pharmaceutical ingredients (APIs) and finished pharmaceuticals from Boehringer-Ingelheim Pharma’s Ingelheim am Rhein, Germany facility. According to an FDA warning letter, an agency inspection found serious violations of…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
current good manufacturing practice requirements for both types of products at the facility.